First-dose pharmacokinetics of lithium carbonate in children and adolescents

Journal of Clinical Psychopharmacology

Volumn 30, Issue 4, 2010, Pages 404-410

  Findling, Robert L ^a   Landersdorfer, Cornelia B ^b   Kafantaris, Vivian ^c   Pavuluri, Mani ^d   McNamara, Nora K ^a   McClellan, Jon ^e   Frazier, Jean A ^f   Sikich, Linmarie ^g   Kowatch, Robert ^h   Lingler, Jacqui ^a   Faber, Jon ^a   Taylor Zapata, Perdita ⁱ   Jusko, William J ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

ⁱ EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

adolescents; bipolar; children; lithium; pharmacokinetics

Indexed keywords

LITHIUM CARBONATE; TRANQUILIZER;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; BIPOLAR I DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; NAUSEA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; AGE; BIOLOGICAL MODEL; BIPOLAR DISORDER; DOSE RESPONSE; DRUG MONITORING; NONLINEAR SYSTEM; ORAL DRUG ADMINISTRATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 77955170999     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181e66a62     Document Type: Article

References (34)

1. Birmaher B, Axelson D. Course and outcome of bipolar spectrum disorder in children and adolescents: a review of the existing literature. Dev Psychopathol. 2006;18:1023-1035.
2. McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:107-125.
3. Muzina DJ, Calabrese JR. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. Aust N Z J Psychiatry. 2005;39:652-661.
4. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2:349-352.
5. Findling RL, Pavuluri MN. Lithium. In: Geller B, DelBello MP, eds. Treatment of Bipolar Disorder in Children & Adolescents. New York, NY: Guilford Press; 2008:43-68.
6. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacologyVdrug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167.
7. Findling RL, Frazier JA, Kafantaris V, et al. The Collaborative Lithium Trials (CoLT): specific aims, methods, and implementation. Child Adolesc Psychiatry Ment Health. 2008;2:21.
8. Amdisen A. Serum level monitoring and clinical pharmacokinetics of lithium. Clin Pharmacokinet. 1977;2:73-92.
9. Thornhill DP. Pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients after acute dosage. Eur J Clin Pharmacol. 1978;14:267-271.
10. Wing YK, Chan E, Chan K, et al. Lithium pharmacokinetics in Chinese manic-depressive patients. J Clin Psychopharmacol. 1997;17:179-184.
11. Vitiello B, Behar D, Malone R, et al. Pharmacokinetics of lithium carbonate in children. J Clin Psychopharmacol. 1988;8:355-359.
12. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980-988.
13. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133: 429-435.
14. Wechsler DA. Wechsler Abbreviated Scale of Intelligence Manual. San Antonio, TX: The Psychological Corporation; 1999.
15. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291-303.
16. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child. 1976;51:170-179.
17. Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr. 1984;104:849-854.
18. Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr. 1985;106:522-526.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
20. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44:1051-1065.
21. Beal SL.Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481-504.
22. Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res. 2008;25:2869-2877.
23. Obach R, Borja J, Prunonosa J, et al. Lack of correlation between lithium pharmacokinetic parameters obtained from plasma and saliva. Ther Drug Monit. 1988;10:265-268.
24. Hunter R. Steady-state pharmacokinetics of lithium carbonate in healthy subjects. Br J Clin Pharmacol. 1988;25:375-380.
25. Gaillot J, Steimer JL, Mallet AJ, et al. A priori lithium dosage regimen using population characteristics of pharmacokinetic parameters. J Pharmacokinet Biopharm. 1979;7:579-628.
26. Yang YY, Yeh EK, Chang SS, et al. Maintenance lithium levels could be lowered: based on Taiwanese and Danish studies. J Formos Med Assoc. 1991;90:509-513.
27. Mason RW, McQueen EG, Keary PJ, et al. Pharmacokinetics of lithium: elimination half-time, renal clearance and apparent volume of distribution in schizophrenia. Clin Pharmacokinet. 1978;3: 241-246.
28. Lehmann W, Kanarkowski R, Matkowski K, et al. Studies of lithium pharmacokinetics in patients with affective illness. Pol J Pharmacol Pharm. 1988;40:47-54.
29. Chen C, Veronese L, Yin Y. The effects of lamotrigine on the pharmacokinetics of lithium. Br J Clin Pharmacol. 2000;50:193-195.
30. Turck D, Heinzel G, Luik G. Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam. Br J Clin Pharmacol. 2000;50:197-204.
31. Ku JS, Wu ZY, Fang YS, et al. Clinical study on the pharmacokinetics of lithium carbonate. Int J Clin Pharmacol Ther Toxicol. 1987; 25:648-650.
32. Jermain DM, Crismon ML, Martin ES 3rd. Population pharmacokinetics of lithium. Clin Pharm. 1991;10:376-381.
33. Reiss RA, Haas CE, Karki SD, et al. Lithium pharmacokinetics in the obese. Clin Pharmacol Ther. 1994;55:392-398.
34. Bergstrand M, Karlsson MO. Handling data below the limit of quantification in mixed effect models. AAPS J. 2009;11:371-380.